AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

Shares of AstraZeneca (AZN) rose 1% on Tuesday morning after it announced that its Calquence (acalabrutinib) in combination ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

UK pharma major AstraZeneca (LSE: AZN) today revealed that its Calquence (acalabrutinib) in combination with bendamustine and ...

(Alliance News) - AstraZeneca PLC on Tuesday said Calquence plus chemoimmunotherapy has been approved in the European Union for previously untreated mantle cell lymphoma in adults.

London open The FTSE 100 is expected to open flat on Tuesday, having closed up 1.17% before the long weekend on Friday at 8,596.35.

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...